Recent research have focused on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and DA neurotransmission. While GCGR activators are increasingly employed for managing type 2 diabetes mellitus, their emerging impacts on motivation circuits, specifically governed by dopaminergic systems, are attracting